Citigroup Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY

Citigroup Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 30.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,707,893 shares of the biopharmaceutical company’s stock after selling 1,197,195 shares during the quarter. Citigroup Inc. owned about 0.13% of Bristol Myers Squibb worth $122,126,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Gateway Investment Advisers LLC boosted its holdings in Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after purchasing an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC boosted its stake in shares of Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares during the last quarter. Commonwealth Retirement Investments LLC boosted its stake in shares of Bristol Myers Squibb by 24.6% during the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after buying an additional 11,690 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after buying an additional 32,476 shares during the last quarter. Finally, Railway Pension Investments Ltd boosted its stake in Bristol Myers Squibb by 3.7% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Stock Up 0.6%

BMY stock opened at $60.66 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $123.53 billion, a P/E ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The company’s 50 day simple moving average is $56.22 and its 200-day simple moving average is $50.00.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the business posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research analyst reports. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. HSBC restated a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Nine equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $60.19.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.